Vir Biotechnology, Inc. (VIR) stock
Close on Nov 11, 2026Market cap $2.22BP/E –Yield –
Vir Biotechnology, Inc. grew revenue 1696.0% to $302.80M over the twelve months to Sep 30, 2026. Free cash flow was -$141.82M. At the latest close the market valued the company at $2.22B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $2.22B
- P/E ratio
- –
- Price to sales
- 7.34
- Price to book
- 2.48
- Dividend yield
- –
- Free cash flow yield
- -6.38%
Fundamentals
- Revenue
- $302.80M
- Net income
- -$184.79M
- EPS, diluted
- -$1.26
- Free cash flow
- -$141.82M
- Book value per share
- $5.29
- Diluted shares
- 169M
Trading
- Next earnings
- Feb 22, 2027 (estimated, after the close)
- Previous close
- $13.15
- Open
- $13.22
- Day's range
- $12.94 – $13.43
- Volume
- 1,292,287
- Average volume (20 days)
- 1,885,898
- Index membership
- S&P SmallCap 600 (since May 2022), Russell 2000 (since Dec 2019), Russell 3000 (since Nov 2019)
- Beta (5 years)
- 0.76
- 52-week range
- $5.32 – $14.38
- RSI (14 days)
- 63.1
- Volatility (1 year)
- 65.7%
- Relative volume
- 0.68×
- WACC
- 8.7%
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | VIR | S&P 500 | Difference | VIR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +12.2% | -2.4% | +14.6 pts | ||
| 3 months | +47.0% | -1.2% | +48.2 pts | ||
| Year to date | +117.7% | +12.3% | +105.5 pts | ||
| 1 year | +129.9% | +12.4% | +117.5 pts | ||
| 3 years | +49.4% | +78.8% | −29.4 pts | +14.3% | +21.4% |
| 5 years | -60.3% | +75.2% | −135.5 pts | -16.9% | +11.9% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Vir Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Update
- Results
- Results
About Vir Biotechnology
Biological Products, (No Diagnostic Substances)
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for serious infectious diseases and cancer. The company utilizes proprietary artificial intelligence antibody engineering and masked T-cell engager platforms to create treatments that enhance immune responses against life-threatening illnesses. Its clinical pipeline includes investigational therapies for chronic hepatitis delta, specifically the combination of tobevibart and elebsiran, as well as T-cell engagers targeting solid tumors, including metastatic castration-resistant prostate cancer, HER2-expressing cancers, and EGFR-expressing cancers. Vir Bio also researches preclinical antibody candidates for HIV, influenza, and coronaviruses. The company targets patients suffering from severe medical conditions with limited therapeutic options, collaborating with global health foundations and commercial biopharmaceutical partners.
Company profile, executives and historyVir Biotechnology stock: common questions
What is Vir Biotechnology's stock price?
VIR closed at $13.13 on Nov 11, 2026, down 0.15% on the day. Over the past 52 weeks it traded between $5.32 and $14.38.
What is Vir Biotechnology's market cap?
Vir Biotechnology was worth $2.22B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is VIR's P/E ratio?
Vir Biotechnology lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.26), so it has no meaningful P/E ratio.
How much revenue does Vir Biotechnology make?
Vir Biotechnology reported revenue of $302.80M for the twelve months to Sep 30, 2026, up 1696.0% from a year earlier.
Does Vir Biotechnology pay a dividend?
No. Vir Biotechnology has not paid a cash dividend over the last twelve months.
When does Vir Biotechnology report earnings next?
Vir Biotechnology is expected to report Q4 FY2026 results on Feb 22, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has VIR stock performed over the past year?
Including dividends, VIR returned +129.9% over the past year, against +12.4% for the S&P 500.
How many VIR shares are sold short?
17M shares were sold short at the latest FINRA report, 12.01% of the float, or 11.9 days of average trading volume.
Who are Vir Biotechnology's competitors?
Companies most similar to Vir Biotechnology by business, industry and size include VXRT, MGTX, IMCR, ADPT, KYMR.
See a number that looks wrong?